Purpose: To summarize a conference convened to examine how cystic fibrosis
screening might appropriately be introduced into routine prenatal practice.
Methods: Participants included experts from various relevant disciplines.
Systematic reviews and data from individual trials were presented; issues w
ere identified and discussed. Results: Judged by published criteria, prenat
al cystic fibrosis screening is suitable for introduction. Screening can be
performed cost-effectively by identifying racial/ethnic groups at sufficie
nt risk and then using either of two models for delivering laboratory servi
ces. Validated educational materials exist. Ethical issues are not unique.
Conclusions: Once adequate facilities for patient and provider education, t
esting, counseling, quality control, and monitoring are in place, individua
l programs can begin prenatal screening for cystic fibrosis.